Pharma companies join forces to block list price disclosure
19-06-2019
Celgene files TM claim against Beacon over psoriasis drug
09-01-2018
Pavel Kapysh / Shutterstock.com
Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Celgene, Amgen, psoriasis, apremilast, otezla, arthritis, acquisition, patent, biosimilar, biologic, inflammation, disease
